Continuing access to ATH434 for multiple system atrophy
Part of Brain & nervous system clinical trials.
This program lets people who already completed a study of the drug ATH434 for multiple system atrophy continue getting the treatment. It is for patients whose doctors believe they may benefit from staying on the medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished a previous study of ATH434 (either study 201 or 202).
- Your regular doctor must think that continuing or restarting ATH434 could help you.
- You cannot have stopped that earlier treatment for any reason.
- You must not have any other serious medical or mental health issue that could make this program risky or not helpful.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial lets people who finished the earlier ATH434-201 study keep getting ATH434 (an experimental drug) on an open-label basis, meaning everyone knows they get the drug. If you were in that study and want to continue, this may help you keep receiving the treatment.
This trial tests whether the drug TEV-56286 continues to work for multiple system atrophy (a rare brain disorder). It is for people who already completed a previous study of the same drug.
This trial tests a new antibody therapy that may target and remove abnormal proteins in the brain linked to Multiple System Atrophy (MSA). It aims to see if the treatment is safe and whether it can help slow the progression of the disease.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This study tests whether a drug called butylphthalide can safely help people with multiple system atrophy (MSA), a rare brain disorder that affects movement and automatic body functions like blood pressure. Participating may help slow the progression of symptoms and improve quality of life.
This trial tests a new stem cell treatment for people with multiple system atrophy (MSA), a rare brain disorder that affects movement and automatic body functions. The treatment uses stem cells from healthy donors, which may help slow down the disease.
Hear when a new Multiple System Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.